The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma

Cancer. 2005 Mar 15;103(6):1314-5; author reply 1315. doi: 10.1002/cncr.20889.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Adult
  • Age Distribution
  • Aged
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology*
  • Case-Control Studies
  • Central Nervous System Neoplasms / epidemiology
  • Central Nervous System Neoplasms / etiology*
  • Central Nervous System Neoplasms / secondary*
  • Cohort Studies
  • Female
  • Humans
  • Incidence
  • Middle Aged
  • Neoplasm Staging
  • Prognosis
  • Receptor, ErbB-2 / analysis
  • Risk Assessment
  • Survival Analysis
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Receptor, ErbB-2
  • Trastuzumab